Scaling peptide synthesis from milligram research quantities to multi-kilogram commercial batches presents unique challenges that require careful planning and technical expertise. The peptide synthesis market is expected to see rapid growth, reaching $9.91 billion in 2030 at a CAGR of 10.1%[reference:94], making scalability an increasingly important capability.
The challenges of scale-up are multifaceted. At larger scales, heat transfer and mixing efficiency become critical factors that can affect reaction kinetics and product quality. Impurity profiles may change as reaction conditions are adjusted, requiring optimization of purification processes. Additionally, the economics of production change dramatically at scale, with raw material costs and process efficiency becoming major considerations.
Successful scale-up requires a systematic approach. We use design of experiments (DoE) to define robust scale-up parameters, identifying critical process parameters and their acceptable ranges. Process modeling helps predict behavior at larger scales, while scale-down studies allow for rapid optimization of conditions using smaller quantities of material.
Our facilities support production from 5mg to >100kg, with seamless technology transfer between scales. We maintain consistent processes across scales, using the same synthesis and purification methods with appropriate modifications for larger equipment. This approach ensures that peptides produced at different scales have comparable quality profiles.
For customers planning clinical development, we recommend early engagement with our process development team to define scale-up strategies. By considering scalability at the earliest stages of development, we can identify potential challenges and develop solutions before they become problems. This proactive approach minimizes risk and ensures that your peptide can be produced at the required scale when needed.